Skip to Content Skip to Search

GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction

GlaxoSmithKline (GSK) announced today that it will no longer pursue global approval (marketing authorisation) for the use of Avodart (dutasteride) to reduce the risk of prostate cancer.

Issued: London UK

GlaxoSmithKline (GSK) announced today that it will no longer pursue global approval (marketing authorisation) for the use of Avodart™ (dutasteride) to reduce the risk of prostate cancer.  The Company will withdraw applications from regulatory review where procedures are ongoing and, in the limited number of countries where dutasteride is already indicated for use in prostate cancer risk reduction, GSK will work with regulatory agencies to remove this indication from the product’s licence and support physicians to communicate appropriately to patients.

The prostate cancer risk reduction applications were based on findings from the Phase III REDUCE trial (REduction by DUtasteride of prostate Cancer Events) which were first presented at the American Urological Association Annual Meeting, April 2009 and subsequently published in the New England Journal of Medicine in 2010.1

As a result of GSK’s continuing evaluation of available data, GSK began filing applications with regulatory agencies worldwide for the use of dutasteride to reduce the risk of prostate cancer from the end of 2009. 

In January 2011, GSK received a Complete Response letter following a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee Meeting (ODAC) in December 2010, when the majority voted against a favourable risk/benefit profile for dutasteride for reduction in the risk of prostate cancer in men at risk for the disease.  This was essentially due toquestions regarding the clinical significance of reducing the risk of low grade prostate cancer, and uncertainties surrounding the possible explanations for the increased number of cases of high grade tumours in men treated with 5-alpha reductase inhibitors (5ARIs) for prostate cancer risk reduction.  Following similar feedback from Sweden, the Reference Member State in Europe, received in February 2011, GSK has now notified the Swedish MPA of its withdrawal from the regulatory review.

Regulatory filings were also made in other countries outside the US and EU resulting in a small number of countries approving the indication.

Overall, a combination of factors including the ongoing medical and scientific debate around the benefits and risks of 5ARIs for prostate cancer risk reduction, together with feedback from regulatory agencies has caused GSK to carefully consider its approach to the indication and subsequently withdraw ongoing applications for approval. 

Dutasteride use in benign prostatic hyperplasia (BPH)

Dutasteride is approved in over 90 countries (as a monotherapy or in combination with tamsulosin) to treat the symptoms of BPH in men with an enlarged prostate and, in some countries, reduction in the risk of acute urinary retention (AUR) and BPH-related surgery*. 

GSK reviews the safety and performance of all its medicines on a continuous basis and is committed to further investigations to advance the understanding of the benefits and risks of dutasteride.  To that end, dutasteride has been extensively studied in clinical trials involving 7,500 men with BPH and has an estimated 6.6 million patient-years of exposure.  As a result of these evaluations, GSK believes that dutasteride for BPH continues to have a favourable risk/benefit profile.

As part of its continuing dialogue with regulatory agencies GSK is working with them to update the existing labels for all dutasteride-containing medicines†.  The update for physicians and patients will include relevant safety information from the REDUCE study and will continue to emphasise the importance of regular PSA monitoring.  GSK will also provide communications to physicians to facilitate awareness and understanding of any changes.

Notes to Editors

About dutasteride

Dutasteride is a dual 5-alpha reductase inhibitor for use to treat symptomatic BPH and reduction in the risk of AUR and BPH-related surgery.  *For specific information on licensed indications, formulations and co-prescription licenses for dutasteride in different countries please see the full prescribing information at www.GSK.com.

† Labels for all dutasteride containing medicines will be updated, including Avodart™, known in some countries as Avolve™ or Avidart™, and Duodart™, known in some countries as Jalyn™ or Combodart™.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

David Mawdsley

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Janet Morgan

(020) 8047 5502

 

David Daley

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

 

Ziba Shamsi

(020) 8047 3289

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jeff McLaughlin

(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.

References

  1. Andriole G, Bostwick D, Brawley O, et al.  Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-1202.